- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 48.18%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | -1.93 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2024 (4) | -2.07 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2023 (3) | -2.89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | -0.09 | -280.0 | 50.0 | -0.23 | -475.0 | 41.03 | -0.09 | 95.34 | 50.0 |
| 25Q4 (7) | 0.05 | 107.69 | 108.06 | -0.04 | 90.48 | 92.16 | -1.93 | 2.53 | 6.76 |
| 25Q3 (6) | -0.65 | 43.97 | -38.3 | -0.42 | 4.55 | 8.7 | -1.98 | -48.87 | -36.55 |
| 25Q2 (5) | -1.16 | -544.44 | -84.13 | -0.44 | -12.82 | 26.67 | -1.33 | -638.89 | -35.71 |
| 25Q1 (4) | -0.18 | 70.97 | 0.0 | -0.39 | 23.53 | 0.0 | -0.18 | 91.3 | 0.0 |
| 24Q4 (3) | -0.62 | -31.91 | 0.0 | -0.51 | -10.87 | 0.0 | -2.07 | -42.76 | 0.0 |
| 24Q3 (2) | -0.47 | 25.4 | 0.0 | -0.46 | 23.33 | 0.0 | -1.45 | -47.96 | 0.0 |
| 24Q2 (1) | -0.63 | 0.0 | 0.0 | -0.60 | 0.0 | 0.0 | -0.98 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.2 | -6.41 | 4.65 | 0.72 | 0.99 | 0.55 | N/A | - | ||
| 2026/3 | 0.22 | 58.78 | 15.83 | 0.52 | -0.35 | 0.52 | 0.63 | - | ||
| 2026/2 | 0.14 | -20.63 | -44.73 | 0.31 | -9.26 | 0.61 | 0.54 | - | ||
| 2026/1 | 0.17 | -43.7 | 84.93 | 0.17 | 84.93 | 0.7 | 0.47 | 主係訂單需求增加所致 | ||
| 2025/12 | 0.3 | 34.29 | 55.99 | 2.33 | 12.71 | 0.72 | 0.46 | 主係訂單需求增加所致 | ||
| 2025/11 | 0.23 | 17.14 | 11.93 | 2.02 | 8.2 | 0.61 | 0.54 | - | ||
| 2025/10 | 0.19 | 2.92 | 26.82 | 1.8 | 7.74 | 0.55 | 0.6 | - | ||
| 2025/9 | 0.19 | 9.72 | 28.08 | 1.6 | 5.83 | 0.53 | 0.67 | - | ||
| 2025/8 | 0.17 | -2.15 | -43.05 | 1.42 | 3.44 | 0.52 | 0.69 | - | ||
| 2025/7 | 0.17 | 1.05 | -1.38 | 1.24 | 16.53 | 0.53 | 0.68 | - | ||
| 2025/6 | 0.17 | -3.26 | 65.53 | 1.07 | 20.1 | 0.54 | 0.72 | 主係訂單需求增加所致 | ||
| 2025/5 | 0.18 | -7.23 | -1.17 | 0.9 | 14.05 | 0.56 | 0.7 | - | ||
| 2025/4 | 0.19 | 3.58 | 32.2 | 0.72 | 18.61 | 0.63 | 0.62 | - | ||
| 2025/3 | 0.19 | -24.24 | 65.45 | 0.52 | 14.29 | 0.52 | 0.71 | 主係訂單需求增加所致 | ||
| 2025/2 | 0.25 | 165.59 | 153.12 | 0.34 | -2.32 | 0.53 | 0.69 | 主係訂單需求增加所致 | ||
| 2025/1 | 0.09 | -52.51 | -62.87 | 0.09 | -62.87 | 0.49 | 0.76 | 主係水產類產品訂單延遲所致 | ||
| 2024/12 | 0.19 | -3.63 | 6.63 | 2.06 | -8.41 | 0.55 | 0.69 | - | ||
| 2024/11 | 0.2 | 32.71 | 4.38 | 1.87 | -9.74 | 0.5 | 0.76 | - | ||
| 2024/10 | 0.15 | 3.94 | -11.2 | 1.67 | -11.2 | 0.6 | 0.63 | - | ||
| 2024/9 | 0.15 | -51.21 | 6.21 | 1.52 | -11.2 | 0.62 | 0.61 | - | ||
| 2024/8 | 0.3 | 69.44 | 59.61 | 1.37 | -12.73 | 0.58 | 0.65 | 主係畜產類產品出貨增加所致 | ||
| 2024/7 | 0.18 | 69.62 | 14.06 | 1.07 | -22.6 | 0.46 | 0.82 | - | ||
| 2024/6 | 0.1 | -42.24 | -45.52 | 0.89 | -27.26 | 0.43 | 1.18 | - | ||
| 2024/5 | 0.18 | 24.09 | 1.02 | 0.79 | -23.86 | 0.44 | 1.16 | - | ||
| 2024/4 | 0.15 | 29.63 | -14.86 | 0.6 | -29.09 | 0.36 | 1.43 | - | ||
| 2024/3 | 0.11 | 15.88 | -64.58 | 0.46 | -32.67 | 0.46 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2024/2 | 0.1 | -61.04 | -26.74 | 0.35 | -4.82 | 0.53 | N/A | - | ||
| 2024/1 | 0.25 | 36.4 | 7.73 | 0.25 | 7.73 | 0.63 | N/A | - | ||
| 2023/12 | 0.18 | -5.66 | -23.76 | 2.25 | -69.93 | 0.55 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/11 | 0.19 | 12.89 | -24.09 | 2.07 | -71.46 | 0.5 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/10 | 0.17 | 24.33 | -51.99 | 1.88 | -73.19 | 0.5 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/9 | 0.14 | -26.69 | -62.39 | 1.71 | -74.33 | 0.48 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/8 | 0.19 | 21.09 | -46.71 | 1.57 | -75.02 | 0.54 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/7 | 0.16 | -18.99 | -53.95 | 1.38 | -76.71 | 0.53 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/6 | 0.19 | 7.1 | -40.33 | 1.22 | -78.09 | 0.54 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/5 | 0.18 | 4.57 | -91.18 | 1.03 | -80.39 | 0.67 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/4 | 0.17 | -46.06 | -80.44 | 0.85 | -73.61 | 0.62 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/3 | 0.32 | 139.69 | -57.5 | 0.68 | -71.06 | 0.68 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/2 | 0.13 | -42.71 | -62.1 | 0.36 | -77.37 | 0.6 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2023/1 | 0.23 | -3.47 | -81.61 | 0.23 | -81.61 | 0.73 | N/A | 新冠PCR產品出貨減少及1月份工作天數較少所致 | ||
| 2022/12 | 0.24 | -6.07 | -75.95 | 7.5 | -25.89 | 0.85 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2022/11 | 0.26 | -28.6 | -57.14 | 7.26 | -20.41 | 0.98 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2022/10 | 0.36 | -2.59 | -42.64 | 7.01 | -17.85 | 1.08 | N/A | - | ||
| 2022/9 | 0.37 | 3.87 | -54.17 | 6.65 | -15.89 | 1.06 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2022/8 | 0.35 | 4.63 | -66.69 | 6.28 | -11.58 | 1.01 | N/A | 新冠PCR產品出貨減少所致 | ||
| 2022/7 | 0.34 | 4.95 | -64.84 | 5.93 | -1.9 | 2.69 | N/A | 因應國內政策致客戶使用量下降，造成新冠PCR產品出貨減少所致 | ||
| 2022/6 | 0.32 | -84.18 | -70.69 | 5.59 | 9.99 | 3.23 | N/A | 因國內政府政策6月新冠PCR產品需求減少及代理商5月備貨所致 | ||
| 2022/5 | 2.03 | 132.07 | 97.89 | 5.27 | 32.24 | 3.66 | N/A | 主係新冠病毒檢測產品銷售增加所致 | ||
| 2022/4 | 0.88 | 17.2 | 39.16 | 3.23 | 9.4 | 1.97 | N/A | - | ||
| 2022/3 | 0.75 | 113.75 | -19.29 | 2.36 | 1.34 | 2.36 | N/A | - | ||
| 2022/2 | 0.35 | -72.21 | -52.86 | 1.61 | 15.01 | 2.61 | N/A | 係因代理商因應春節假期於1月底啟動備貨，致2月營收較同期減少 | ||
| 2022/1 | 1.26 | 26.23 | 91.74 | 1.26 | 91.74 | 2.85 | N/A | 主係新冠病毒檢測產品銷售增加所致 | ||
| 2021/12 | 1.0 | 67.44 | -3.78 | 10.12 | 18.09 | 2.22 | N/A | - | ||
| 2021/11 | 0.6 | -4.45 | -51.99 | 9.12 | 21.1 | 2.02 | N/A | 因去年同期銷售名台新冠病毒檢測設備所致 | ||
| 2021/10 | 0.62 | -22.16 | 9.29 | 8.53 | 35.51 | 2.49 | N/A | - | ||
| 2021/9 | 0.8 | -24.51 | 30.95 | 7.9 | 38.12 | 2.82 | N/A | - | ||
| 2021/8 | 1.06 | 10.44 | 45.65 | 7.1 | 38.98 | 3.12 | N/A | - | ||
| 2021/7 | 0.96 | -12.5 | 84.71 | 6.04 | 37.87 | 3.09 | N/A | 主係新冠病毒檢測產品銷售增加所致。 | ||
| 2021/6 | 1.1 | 6.82 | 54.19 | 5.08 | 31.56 | 0.0 | N/A | 主係新冠病毒檢測產品銷售增加所致 | ||
| 2021/5 | 1.03 | 63.2 | -2.22 | 3.98 | 26.45 | 0.0 | N/A | - |